Ulixertinib (BVD-523)

For research use only. Not for use in humans.

目录号：S7854 别名： VRT752271

Ulixertinib (BVD-523) Chemical Structure

CAS No. 869886-67-9

Ulixertinib (BVD-523, VRT752271)是有效的可逆ERK1/ERK2抑制剂，其抑制ERK2的IC50<0.3 nM 。Phase 1。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1859.13	现货
5mg	RMB 1222.42	现货
25mg	RMB 3643.55	现货
100mg	RMB 8157.89	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ulixertinib (BVD-523)发表文献28篇：

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

EMBO Rep, 2020, e48686

PubMed: 32484300 ( click the link to review the publication )

Mol Cancer, 2020, 19(1):139

PubMed: 32907612 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Front Immunol, 2020, 11:1028

PubMed: 32536926 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Front Microbiol, 2020, 10:2936

PubMed: 32038511 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Rep, 2019, 29(1):118-134

PubMed: 31577942 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):642-654

PubMed: 30275173 ( click the link to review the publication )

Front Oncol, 2019, 9:958

PubMed: 31632904 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Int Immunopharmacol, 2019, 70:504-511

PubMed: 30884430 ( click the link to review the publication )

Blood, 2018, 131(18):2047-2059

PubMed: 29496671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3679

PubMed: 30206219 ( click the link to review the publication )

Haematologica, 2018, 10.3324/haematol.2018.196931

PubMed: 30262568 ( click the link to review the publication )

Chem Sci, 2018, 9(9):2419-2431

PubMed: 29732117 ( click the link to review the publication )

Oncotarget, 2018, 9(60):31572-31589

PubMed: 30167080 ( click the link to review the publication )

Cell Mole Bioeng, 2018, 10.1007/s12195-018-0542-y

PubMed: ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1028

PubMed: 30352565 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):107

PubMed: 28797284 ( click the link to review the publication )
PLoS One, 2017, 12(10):e0185862

PubMed: 28982154 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44295-44311

PubMed: 28574828 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Int J Clin Exp Med, 2016, 9(6):10955-10962

PubMed: ( click the link to review the publication )

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述

Ulixertinib (BVD-523, VRT752271)是有效的可逆ERK1/ERK2抑制剂，其抑制ERK2的IC50<0.3 nM 。Phase 1。

靶点

ERK1 ^[1]	ERK2 ^[1]
	<0.3 nM

体外研究

在一个包含b-RAFV600E突变体的A375黑色素瘤细胞中，Ulixertinib降低磷酸化的ERK2 (pERK)水平和下游激酶RSK (pRSK)的磷酸化水平，IC50分别为4.1/0.14 μM。Ulixertinib也会抑制A375细胞增殖，IC50为180 nM。^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
A375	MmDYSpVv[3Srb36gZZN{[Xl?		MnjsTY5pcWKrdHnvckBw\iCHUluyJIlvKGi3bXHuJGE{PzViY3XscJMhcGG{Yn;ybY5oKEKUQV[gWlYxOEVibYX0ZY51KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJJBpd3OyaH;yfYxifGWmIGLTT{Bt\X[nbIOsJGlEPTBiPTCwMlA{OSEQvF2u	NIP6OXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO3OlMxPid-MkizO\|Y{ODZ:L3G+
A375	MVfGeY5kfGmxbjDhd5NigQ>?	MoXFNkBpenN?	NUjUWYpiUW6qaXLpeIlwdiCxZjDFVmsyNzJiaX6gbJVu[W5iQUO3OUBk\WyuczDoZZJjd3KrbnegRk1TSUZiVk[wNGUhdXW2YX70JIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIIDoc5NxcG9vUmPLJIxmfmWuIHHmeIVzKDJiaILzJIJ6KEOnbHzvcYlkeyCDcoLhfXNk[W6WTTDWWGkhcW2jZ3nu[{BidmGueYPpd{whUUN3MDC9JFAvOTRizszNMi=>	Ml;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7N{e5PFEoRjJ3OUe3PVgyRC:jPh?=
A375	NXSzUW1USW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	NFTsTYE4OiCqcoO=	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF\|N{WgZ4VtdHNiaHHyZo9zcW6pIFKtVmFHKFZ4MEDFJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscI9ucWO\|IFHydoF6W2OjbmTNJHZVUSCrbXHnbY5oKGGwYXz5d4l{NCCLQ{WwJF0hOC5zODFOwG0v	NXfWbG1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5O\|c6QDFpPkK1PVc4QThzPD;hQi=>
SKCO1	NG\J[ZpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MmXVO\|IhcHK\|	NYjvZYNOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT2NQOSClZXzsd{Bp[XKkb4LpcochU1KDUzDHNVJXKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvOzV4IN88UU4>	M2XPV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4PVQxLz5{OECzPFk1ODxxYU6=
BA/F3	M4rafWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NI[5Wnk4OiCqcoO=	NH\CSG9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIhiemKxcnnu[{BMWkGVIFexNmQhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNE41PjhizszNMi=>	M{\vZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4PVQxLz5{OECzPFk1ODxxYU6=
SW620	Mn;vRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MWW3NkBpenN?	NH7r[2VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXOlIxKGOnbHzzJIhiemKxcnnu[{BMWkGVIFexNnYhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNE41QTlizszNMi=>	NWrKO2xWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g6PDBpPkK4NFM5QTRyPD;hQi=>
AsPC1	NEXnd2NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	M13ud\|czKGi{cx?=	M3vwOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQYPQR\|Eh[2WubIOgbIFz[m:{aX7nJGtTSVNiR{GySEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGlEPTBiPTCwMlg1QSEQvF2u	NUDxUVhwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g6PDBpPkK4NFM5QTRyPD;hQi=>
NCI-H23	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MlLlO\|IhcHK\|	M{D0TmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOyClZXzsd{Bp[XKkb4LpcochU1KDUzDHNVJEKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFEh\|ryPLh?=	MoXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{i5OFAoRjJ6MEO4PVQxRC:jPh?=
SW156	NFTiWWhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	NHjSVJA4OiCqcoO=	NIG4SldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXNVU3KGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhU1KDUzDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEGuNlQh\|ryPLh?=	M2XjfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4PVQxLz5{OECzPFk1ODxxYU6=
BA/F3	M1vnXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MlnIO\|IhcHK\|	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMj6yN\|Eh\|ryPLh?=	M4L1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4PVQxLz5{OECzPFk1ODxxYU6=
A375	NW\Bbph6TnWwY4Tpc44h[XO\|YYm=	NWXVdm93OiCqcoO=	MmqzTY5pcWKrdHnvckBw\iCHUluyJIlvKGi3bXHuJGE{PzViY3XscJMhcGG{Yn;ybY5oKEJvUlHGJHY3ODCHIH31eIFvfCCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBxcG:\|cHjvMWVTUzJibHX2[Ywh[W[2ZYKgNkBpenNiYomgR4VtdG:vaXPzJGFzemG7U3PhcnROKF[WSTDpcYFocW6pIHHuZYx6e2m\|LDDJR\|UxKD1iND6xJO69VS5?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl5N{m4NUc,OjV7N{e5PFE9N2F-
A375	M4H6bmZ2dmO2aX;uJIF{e2G7		NXO2[XI{UW6qaXLpeIlwdiCxZjDFVmszKGmwIHj1cYFvKEF\|N{WgZ4VtdHNiaHHyZo9zcW6pIFLSRWYhXjZyMFWgcZV1[W62IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGVTUzJibHX2[Yx{NCCLQ{WwJF0hPC5zIN88UU4>	NHruS2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO3OlMxPid-MkizO\|Y{ODZ:L3G+
BA/F3	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MYG3NkBpenN?	NHfiNodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIhiemKxcnnu[{BMWkGVIFexNmQhdXW2YX70JIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBKVC1\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA5NjZyODFOwG0v	MnnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{i5OFAoRjJ6MEO4PVQxRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / RRM2 ; PubMed: 28797284 J Exp Clin Cancer Res PANC-1 and BxPC-3 cells were treated with 1 nM of the ERK inhibitor ulixertinib for 24 h. The protein levels of p-ERK, ERK, and RRM2 were detected using western blot analysis.	28797284
Growth inhibition assay	Cell viability ; PubMed: 30771617 Mol Ther Nucleic Acids Caki-1 and 786-O cells were treated with everolimus alone or in combination with ERK inhibitor BVD-523 for 72 h. The cell viability was assessed by CCK-8 assay. p < 0.01; *p < 0.001.	30771617

激酶实验：^[1]	- 合并 ERK2催化抑制的Rapidfire质谱分析试验: MEK U911活化的ERK2蛋白在组织内部表达并纯化。酶和底物溶液在包含50 mM Tris (pH 7.5)，10 mM MgCl₂，0.1 mM EGTA，10 mM DTT 和 0.01% (v/v) CHAPS的试验缓冲液中制备。1.2 nM ERK2蛋白质在试验缓冲液中制备，将10μL加入包含测试和对照品化合物的聚丙烯384孔板的每个孔中。化合物板预先加入范围为100μM 到0.1 nM 的12个不同剂量，以计算化合物IC50s，与1%试验化合物中总DMSO浓度。酶和化合物在室温下预培养20分钟后，10μL 底物溶液加入16μM Erktide (IPTTPITTTYFFFK)和120μM ATP (测量Km) 组成的试验缓冲液中。反应在室温下进行20分钟，然后加入80μL 1% (v/v)甲酸淬灭反应。然后试验板在RapidFire质谱分析平台上运行以测量底物(未磷酸化的Erktide)和产物(磷酸化的Erktide)。
细胞实验：^[1]	- 合并 Cell lines: A375 细胞 Concentrations: ~30 μM Incubation Time: 72小时 Method: A375细胞在DMEM，10% (v/v)胎牛血清和1% (v/v) L-谷氨酰胺组成的细胞培养基中培养。采集后，将细胞分别加入黑色384孔Costar板，在40μL总体积的细胞培养基中使每孔含有200个细胞，然后在37℃，90%相对湿度和5% CO₂旋转式培养基中培养过夜。使用Labcyte Echo 555声控分配器将测试化合物和对照品直接给药至细胞板内部308孔。细胞在30 μM到0.03 nM范围内以12个不同浓度给药，计算化合物IC50s，与0.3%试验化合物中总DMSO浓度。然后细胞板在37℃下培养72小时。将细胞中加入20 μL 含12%甲醛的PBS/A (4%终浓度) 和1:2000稀释的Hoechst 33342固定并着色，在室温下培育30分钟，然后用PBS/A洗涤。使用Cellomics ArrayScanTM VTI成像平台在着色的细胞平板上计数细胞。在第0天，细胞板依然固定，着色，并读取数据生成细胞计数基线，以测定化合物细胞毒性以及抗增殖作用。 (Only for Reference)

参考文献

[1] Ward RA, et al. J Med Chem. 2015, 58(11), 4790-4801.

溶解度 (25°C)

体外	DMSO	86 mg/mL (198.46 mM)
	Ethanol	15 mg/mL (34.61 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ulixertinib (BVD-523) SDF

分子量	433.33
化学式	C₂₁H₂₂Cl₂N₄O₂
CAS号	869886-67-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	VRT752271

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

g

每只动物给药体积

ul

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04488003	Recruiting	Drug: Ulixertinib\|Drug: Physician''s Choice	Advanced Solid Tumor\|BRAF Gene Mutation\|BRAF Gene Alteration\|MEK Mutation\|MEK Alteration\|MAP2K1 Gene Mutation\|MAP2K1 Gene Alteration\|MAP2K2 Gene Mutation\|MAP2K2 Gene Alteration	BioMed Valley Discoveries Inc	November 3 2020	Phase 2
NCT04145297	Recruiting	Drug: Ulixertinib\|Drug: Hydroxychloroquine	Gastrointestinal Neoplasms	University of Utah\|BioMed Valley Discoveries Inc	March 17 2020	Phase 1
NCT03698994	Recruiting	Other: Pharmacokinetic Study\|Drug: Ulixertinib	Advanced Malignant Solid Neoplasm\|MAPK1 Gene Mutation\|Recurrent Ependymal Tumor\|Recurrent Ewing Sarcoma\|Recurrent Glioma\|Recurrent Hepatoblastoma\|Recurrent Histiocytic and Dendritic Cell Neoplasm\|Recurrent Langerhans Cell Histiocytosis\|Recurrent Malignant Germ Cell Tumor\|Recurrent Malignant Solid Neoplasm\|Recurrent Medulloblastoma\|Recurrent Neuroblastoma\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Osteosarcoma\|Recurrent Peripheral Primitive Neuroectodermal Tumor\|Recurrent Primary Malignant Central Nervous System Neoplasm\|Recurrent Rhabdoid Tumor\|Recurrent Rhabdomyosarcoma\|Recurrent Soft Tissue Sarcoma\|Refractory Ependymoma\|Refractory Ewing Sarcoma\|Refractory Glioma\|Refractory Hepatoblastoma\|Refractory Histiocytic and Dendritic Cell Neoplasm\|Refractory Langerhans Cell Histiocytosis\|Refractory Malignant Germ Cell Tumor\|Refractory Malignant Solid Neoplasm\|Refractory Medulloblastoma\|Refractory Neuroblastoma\|Refractory Non-Hodgkin Lymphoma\|Refractory Osteosarcoma\|Refractory Peripheral Primitive Neuroectodermal Tumor\|Refractory Primary Malignant Central Nervous System Neoplasm\|Refractory Rhabdoid Tumor\|Refractory Rhabdomyosarcoma\|Refractory Soft Tissue Sarcoma\|Wilms Tumor	National Cancer Institute (NCI)	October 1 2018	Phase 2
NCT02994732	Completed	Drug: [14C]-BVD-523	Healthy	BioMed Valley Discoveries Inc	January 2017	Phase 1
NCT02296242	Completed	Drug: BVD-523	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome	BioMed Valley Discoveries Inc	November 2014	Phase 1\|Phase 2

研究领域

产品类型

定制您的化合物库

Ulixertinib (BVD-523)

客户使用Selleck生产的Ulixertinib (BVD-523)发表文献28篇：

产品安全说明书

ERK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ulixertinib (BVD-523) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

ERK Signaling Pathway Map